| Aethlon Medical Discloses FDA Meeting Request and Proposed Expansion of U.S. ... - PR Newswire (press release) |
|
|
PR Newswire (press release) The Hemopurifier® is also uniquely suited to treat HCV-infected End-stage renal disease (ESRD) patients, whose condition limits their ability to be treated with HCV-SOC. The incidence of HCV infection in ESRD patients is approximately 100-1000 times |